hotspot -WSS

hotspot

author：explore 2025-09-29 18:16:09 - browse：2

Chemotherapy infusion — The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Are infertility treatments 'essential' during the Covid

WSS

A new ‘biological computer' targets cancer while sparing healthy cells

Readout LOUD podcast: How biotech is using artificial intelligence

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Senators start work on Medicare physician payment reform

A disappointing year of Humira biosimilars

Biden report: The neurospychology of memory and aging

leisure time

hotspot

hotspot

How one medical school became remarkably diverse

The Readout: Gilead, Bernie Sanders, and other pharma news

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Alkermes shareholders re

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare threatens to cut off funding for HCA's Mission hospital

Psychedelics group wrestles with new pharma identity

Key House Republican on health care plans exit from Congress

focus

Scientists grapple with ethics of stem cell research

What we’ve learned from the Aduhelm mess

Judge denies Trump's request for new trial in E. Jean Carroll case

Scientists grapple with ethics of stem cell research

Caribou posts encouraging results on off

When a patient nears the end, a feared therapy can comfort

entertainment

hotspot

hotspot

explore